Rotablation or Balloon Immediate and 6 month results of a trial in patients with chronic total coronary occlusion Layth A. Mimish, M. Bakhshi, J. Buraiki,

Slides:



Advertisements
Similar presentations
ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,
Advertisements

M.Unverdorben; ACC March 2008 Martin Unverdorben Rotenburg/Fulda, Germany and Richmond, VA, USA Clinical Research Institute, Center for Cardiovascular.
BIFURCATION LESIONS Dr. Tahsin.N
AVE Micro Stent KFSH & RC Experience with 6 months Angiographic Follow Up Layth A. Mimish, M. Bakhshi, F. Al-Nozha, A. Kinsara, O. Amoudi, J. Buraiki,
Complications of HSRA Layth A. Mimish Consultant Cardiologist Cardiovascular Consultants Group Jeddah, Saudi Arabia.
Directional Coronary Atherectomy KFSH & RC Experience Layth A. Mimish, J. Buraiki, M. E. Fawzy, B. Dunn, M. Bakhshi, B. Dajani.
30 th Annual Meeting of The Egyptian Society of Cardiology.
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
FAST (Femoral Artery Stenting Trial) Final Results Hans Krankenberg (on behalf of the FAST Investigators) Hamburg University Cardiovascular Center Prof.
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
Call for CASES Staged PCI in a patient with multivessel coronary disease disqualified from CABG. Pawel Buszman, MD, FESC, FSCAI Marcin Debinski, MD Krzysztof.
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides
Aims To evaluate the technical and clinical outcome of percutaneous transluminal infra-popliteal angioplasties (PTIA) +/- stenting in a subgroup of patients.
Unstable angina and arterial hypertension Leszek Kinasz, MD American Heart of Poland Ustron, Poland.
Qu Xinkai Shanghai Chest Hospital Shanghai Jiaotong University Value of comprehensive cardiac evaluation using MSCT in patients with CTO.
Technical approach PCI in Small Vessels Washington Cardiology Center Augusto Pichard, L. Satler, K. Kent, R. Waksman, J. Laird, W. Suddath, J. Sharretts,
Tetra Randomized European Direct Stenting Study (TRENDS)
Featuring CTO Complex-PCI by Trans-radial Approach CTO Case review 5 French TRI CTO of right coronary artery -5 F Launcher guiding Catheter (right Judkins.
AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
Retrograde approach for the Recanalizaiton of Coronary CTO: Preliminary Experience of Single Centre Lei Ge, Juying Qian, Xuebo Liu, Qin Qing, Junbo Ge.
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
David Hildick-Smith Sussex Cardiac Centre. Background to ARTS Previous POBA studies Meta-analysis 3300 patients 1660 CABG, 1710 PTCA Deaths 79 PCI vs.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
Direct Stenting is Better (Debate Session) 동아의대 김 무 현.
ROTAXUS A Prospective, Randomized Trial of High-Speed Rotational Atherectomy Prior to Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
: PROFI : A Prospective, Randomized Trial of Proximal Balloon Occlusion vs. Filter Embolic Protection in Patients Undergoing Carotid Stenting Klaudija.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Multivessel Coronary Artery Disease
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Retrograde Techniques and the Impact of Operator.
The CIAO (Coronary Interventions Antiplatelet-based Only) Study Eugenio Stabile, MD, PHD, FESC, FAHA, Wail Nammas, MD, Luigi Salemme, MD, Giovanni Sorropago,
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Novel Modification of the Retrograde Approach.
Ms. Leonardo Roever Coronary Stents. Coronary Artery Disease Leading cause of death in United States for men and women Caused by buildup of plaque in.
Influence of a Pressure Gradient Distal to Implanted Bare-Metal Stent on In-Stent Restenosis After Percutaneous Coronary Intervention Lisette Okkels Jensen,
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Percutaneous Treatment of Protected and Unprotected.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting.
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
The Endocross Enabler-P: First in-Human Results
Interesting Case Presentation
From: Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal StentsThe TAXUS V ISR Randomized Trial JAMA. 2006;295(11):
Layth A. Mimish, M. Bakhshi, J. Buraiki,
Angiographic Features of Atherosclerotic Superficial Femoral Artery Disease in Diabetics and Non-diabetics Presenting with Claudication Atif Mohammad,
How to do endovascular mechanical thrombaspiration
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
Recanilization of Central Venous Total Occlusions
OCT-Guided PCI What needs to be done to establish criteria?
Long-term follow-up of the DIABETES I (DIABETes and sirolimus Eluting Stent) trial: P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín,
American College of Cardiology Presented by Dr. Stephan Windecker
REALITY: 8 month results
TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.
Giuseppe Biondi Zoccai, MD
Presented at ACC 2003 Late Breaking Clinical Trials
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Drug-eluting stents for in-stent restenosis
Percutaneous revascularization strategies in a patient with previous coronary artery bypass surgery: Technical and patho-physiological insights  Pierfrancesco.
ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS
Impact of Diabetes Mellitus on Long-term Outcomes in the
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
American College of Cardiology Presented by Dr. Adnan Kastrati
The American College of Cardiology Presented by Dr. A. Abazid
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

Rotablation or Balloon Immediate and 6 month results of a trial in patients with chronic total coronary occlusion Layth A. Mimish, M. Bakhshi, J. Buraiki, F. Nozha, K. Niazi, B. Dunn, B. Dajani, M.E. Fawzy

The Goal of the Study u PTCA of chronic total occlusion carries high restenosis rate u Main mechanism of GOBA is controlled dissection/++Trauma u Smoother lumen is created by debulking with rotablation u Does that reflect on restenosis rates?

Study Patients/Design u All patients undergoing percutaneous revascularization of occluded coronary artery of more than 3 months duration u Informed Consent u After crossing the lesion with the wire patients are randomized to one limb of the study

Study Patient/Design u For rotablator patients the wire is exchanged to Rota wire using Buchbinder exchange catheter u All rotablations are chased with low atmospheric inflations to achieve residual stenosis of less than 20%

Study Patient/Design u Multiple angiographic views with assessment of collaterals, length of lesion, LVEF, Segmental analysis u 10,000 U I.V. Heparin followed by check of ACT u I.C. NTG and/or Verapamil as required

Study Patient/Design u Balloon size is judged by the size of the artery in the immediate proximity of the lesion u Preferably single balloon of matching size is used u Only if failure to cross with deep throating with the guider, a pre dilation with 1.5 mm balloon is used

Study Patient/Design u Smallest Burr size available is used followed by larger size/s Burrs aiming to achieve at least 30% residual stenosis u All rotablated cases are chased with balloon dilatation u Stenting is used only for dissection or for residual narrowing of more than 30%

Demographic/Clinical Data u No. of patients u Males/females u Mean Age u Hypertension u Diabetes u Smokers u Duration/m PTCA Rota P value NS NS 16/6 17/4 NS 16/6 17/4 NS NS NS 7/22 8/21 NS 7/22 8/21 NS 6/22 12/21 NS 6/22 12/21 NS 9 15 NS 9 15 NS NS NS

Angiographic/Clinical Data u LVEF u Collaterals u Vessel Size u Length u Dissection u Stenosis/Post u Floro Time PTCA Rota P value NS NS NS NS NS NS 10 8 NS 10 8 NS NS NS

Shortcomings & Pitfalls u Small number of patients u Visual assessment u Contamination with stenting u Ballooning post rotablations

6 Months Follow Up u Angiographic follow up showed significant restenosis in 10 patients in each group i.e. 45% Vs 47% ( P=N.S.) u Stenting ( 1 in PTCA group and 7 in Rotablator group ) did not affect the restenosis rates

Conclusions u Rotablation does not significantly decrease the rate of restenosis u It definitely increases the cost and the time of the procedure u It exposes the team and the patient to higher dose of radiation